Summary
MYD Chart
MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down
Myriad Genetics jumps 21% after Q4 earnings beat estimates by 350% and revenues top forecasts, even as gross margin slips and mental health sales decline.
Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript
Myriad Genetics, Inc. (MYGN) Q4 2025 Earnings Call Transcript
Here's What Key Metrics Tell Us About Myriad (MYGN) Q4 Earnings
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Myriad Genetics Inc. (MYD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Myriad Genetics Inc. ever had a stock split?
Myriad Genetics Inc. Profile
| Professional Services Industry | Industrials Sector | Samraat S. Raha CEO | XBER Exchange | US62855J1043 ISIN |
| US Country | 2,700 Employees | - Last Dividend | 26 Mar 2009 Last Split | 5 Oct 1995 IPO Date |
Overview
Myriad Genetics, Inc., established in 1992 and headquartered in Salt Lake City, Utah, is a forefront company in the genetic testing and precision medicine landscape, operating both within the United States and on an international scale. The company takes pride in its development of cutting-edge molecular diagnostic tests across three main areas: oncology, women's health, and pharmacogenomics. Its mission to revolutionize patient care through genetic insights is further bolstered by strategic collaborations with renowned institutions and companies such as Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health.
Products and Services
- MyRisk Hereditary Cancer Test: A sophisticated DNA sequencing test aimed at evaluating the risk factors for hereditary cancers.
- BRACAnalysis CDx Germline Companion Diagnostic Test: This DNA sequencing test is crucial for determining suitable therapy options for patients suffering from certain types of metastatic cancers, specifically when they show deleterious or suspected harmful germline BRCA variants.
- MyChoice CDx Companion Diagnostic Test: A vital tumor analysis for assessing the homologous recombination deficiency status in ovarian cancer patients, guiding therapeutic decisions.
- Prolaris Prostate Cancer Prognostic Test: An RNA expression analysis focusing on the aggressiveness of prostate cancer, aiding in the management and treatment planning.
- EndoPredict Breast Cancer Prognostic Test: Utilizes RNA expression to evaluate the level of aggressiveness in breast cancer, offering critical insights for treatment strategies.
- Precise Tumor: Offers comprehensive solutions for precision oncology, tailoring cancer treatment to the individual’s genetic profile.
- Prequel Prenatal Screen: A non-invasive screening conducted through maternal blood to detect severe chromosomal disorders in the fetus early in the pregnancy.
- Foresight Carrier Screen: A prenatal test designed for future parents to determine their risk of passing on recessive genetic conditions to their child.
- SneakPeek: A non-invasive blood test that accurately predicts the fetal gender, providing expecting parents with early insights.
- GeneSight Psychotropic Mental Health Medication Test: A DNA genotyping test developed to assist in the selection of appropriate psychotropic medications for patients with depression, anxiety, ADHD, and other mental health conditions.
